key: cord-0974377-i0qxhhgz authors: Ahmed, Amr; Nezami, Mohammad; Alkattan, Abdullah title: Pitfalls at Chemistry of Adenoviral Vector Vaccine against COVID-19 and How to Circumvent it date: 2021-08-07 journal: Adv Pharm Bull DOI: 10.34172/apb.2022.024 sha: f53de3677fcdd05715e22eca642a546f81b831c8 doc_id: 974377 cord_uid: i0qxhhgz nan Nevertheless, the EDTA-induced thrombocytopenia is a risk phenomenon caused by EDTA-dependent anti-platelet auto-antibodies that identify antigens modified by EDTA. Few case reports indicating that thrombocytopenia and thrombosis events after receiving the vaccines containing EDTA cannot be ruled out. 5, 6 The cation chelation by EDTA causes changes in the shape of the platelet membrane glycoprotein IIb-IIIa complex and showed an obscure epitope that becomes available for autoantibodies. 7 This leads to platelet clumping and aggregation in vitro, leading to low platelet counts, which slightly increase in white blood cells. 8 Another issue is the adenovirus in the vaccine. It can induce thrombocytopenia, a potentially severe complication of gene therapy protocols by this kind of vector. While studying the interaction between adenovirus and platelets, we proved adenovirus platelet attachment by detecting Coxsackie adenovirus receptor. We concluded that the interaction between platelets and adenovirus causes platelet activation and quick appearance of P-selectin on the platelet's surface; this triggers the formation of platelet-leukocyte aggregates. This interaction is vital since it promotes leukocyte rolling on the endothelium and slows platelets that excrete the ligand in an inflammatory setting. The thrombocytopenia appearance in 24 hours of adenovirus administration reveals that this is a response to the virus. Studies of the administered adenovirus show that liver macrophages clear most of the virus within 24 hours, the same amount of time that platelets take to be cleared. According to this observation, we can conclude that the adenovirus and the activated platelets may be cleared with the same mechanism. For further evidence, we noticed the adenovirus particles' appearance in the liver macrophage 10 minutes after the injection. 9 Many interactions are acknowledged to occur between Ad capsid and non-cellular and cellular blood components, in addition to the complement system. For instance, Ad vectors interact with platelets, causing thrombocytopenia. 10, 11 The most difficult obstacle for Ad vectors comes from the stimulation of an intense immune response, possibly caused by reacting with antigen-presenting cells like dendritic cells and macrophages; this causes the release of pro-inflammatory cytokines/chemokines like tumor necrosis factor-α, interferon γ, inducible protein-10, RANTES, and interleukin 6 (IL-6). 12 Because the spleen is the primary location of cytokine and chemokine synthesis, such as interleukin-6, decreased absorption of PEGylated vectors by the spleen could indicate why lower IL-6 concentrations were seen following PEGylated Ad vector delivery. PEGylated Ad vectors demonstrated much-decreased spleen (3-fold lower) and kidney transduction, according to De Geest et a1 13 (2.5-fold lower). PEGylation further prevented thrombocytopenia from developing. Finally, combining PEGylation of adenoviral vectors with methylprednisolone injection increases the therapeutic index of adenoviral gene transfer. 13 PEGylation has already resulted in a 70% reduction in serum IL-6 concentrations. 14 We noted that the study by Ewer et al studied immune response by a single dose of ChAdOx1 nCov-19, not included the test of Il-6. 15 We conclude from previous studies that the PEGylating of adenoviral vectors can be promise technology as safety profile as significantly reduced IL-6 and liver toxicity and how avoiding the pitfalls of chemistry and virology, so the PEGylation since the first time in 1999 introduced by O'Riordan et al 16 need more advancements. Not applicable. COVID-19 Vaccine AstraZeneca That zincing feeling: the effects of EDTA on the behaviour of zinc-binding transcriptional regulators Three conformational states of the p300 CH1 domain define its functional properties The CBP/ p300 TAZ1 domain in its native state is not a binding partner of MDM2 Ethylenediaminetetraacetic acid (EDTA)-induced thrombocytopenia: a case report Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up A case of EDTAdependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons Intravenous administration of replicationincompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo None.